X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ORCHID PHARMA LTD - Comparison Results

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA ORCHID PHARMA LTD AJANTA PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 27.9 -0.7 - View Chart
P/BV x 11.5 0.5 2,449.4% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 AJANTA PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
ORCHID PHARMA LTD
Sep-13
AJANTA PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs1,720194 886.6%   
Low Rs1,10335 3,151.4%   
Sales per share (Unadj.) Rs194.6276.5 70.4%  
Earnings per share (Unadj.) Rs45.2-79.2 -57.1%  
Cash flow per share (Unadj.) Rs50.3-43.5 -115.8%  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.053.9 244.8%  
Shares outstanding (eoy) m88.7770.45 126.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.30.4 1,751.3%   
Avg P/E ratio x31.2-1.4 -2,159.4%  
P/CF ratio (eoy) x28.1-2.6 -1,065.0%  
Price / Book Value ratio x10.72.1 503.6%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,2998,067 1,553.3%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m2,5702,527 101.7%   
Avg. sales/employee Rs ThNM6,956.1-  
Avg. wages/employee Rs ThNM902.5-  
Avg. net profit/employee Rs ThNM-1,993.0-  
INCOME DATA
Net Sales Rs m17,27519,477 88.7%  
Other income Rs m166407 40.8%   
Total revenues Rs m17,44219,884 87.7%   
Gross profit Rs m5,8071,103 526.7%  
Depreciation Rs m4512,519 17.9%   
Interest Rs m495,227 0.9%   
Profit before tax Rs m5,474-6,236 -87.8%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m1,460-125 -1,166.1%   
Profit after tax Rs m4,014-5,580 -71.9%  
Gross profit margin %33.65.7 593.8%  
Effective tax rate %26.72.0 1,328.4%   
Net profit margin %23.2-28.7 -81.1%  
BALANCE SHEET DATA
Current assets Rs m7,63911,014 69.4%   
Current liabilities Rs m2,71532,060 8.5%   
Net working cap to sales %28.5-108.1 -26.4%  
Current ratio x2.80.3 819.1%  
Inventory Days Days4395 45.6%  
Debtors Days Days7934 234.4%  
Net fixed assets Rs m6,91429,440 23.5%   
Share capital Rs m177705 25.1%   
"Free" reserves Rs m11,4422,043 560.2%   
Net worth Rs m11,7213,800 308.4%   
Long term debt Rs m1499,018 1.6%   
Total assets Rs m14,81446,510 31.9%  
Interest coverage x112.9-0.2 -58,483.2%   
Debt to equity ratio x02.4 0.5%  
Sales to assets ratio x1.20.4 278.5%   
Return on assets %27.4-0.8 -3,608.5%  
Return on equity %34.2-146.9 -23.3%  
Return on capital %46.5-3.7 -1,245.9%  
Exports to sales %55.137.9 145.6%   
Imports to sales %6.022.6 26.6%   
Exports (fob) Rs m9,5277,378 129.1%   
Imports (cif) Rs m1,0384,406 23.5%   
Fx inflow Rs m10,4227,513 138.7%   
Fx outflow Rs m1,6785,649 29.7%   
Net fx Rs m8,7441,865 469.0%   
CASH FLOW
From Operations Rs m3,2641,682 194.1%  
From Investments Rs m-2,093-9,860 21.2%  
From Financial Activity Rs m-1,1866,644 -17.8%  
Net Cashflow Rs m-15-1,535 1.0%  

Share Holding

Indian Promoters % 73.8 32.3 228.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 4.6 33.7%  
FIIs % 7.6 3.3 230.3%  
ADR/GDR % 0.0 4.6 -  
Free float % 17.0 55.3 30.7%  
Shareholders   20,968 84,811 24.7%  
Pledged promoter(s) holding % 4.4 54.9 8.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   DIVIS LABORATORIES  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 17, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS